<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579991</url>
  </required_header>
  <id_info>
    <org_study_id>MRU20200001</org_study_id>
    <nct_id>NCT04579991</nct_id>
  </id_info>
  <brief_title>Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women</brief_title>
  <official_title>Effects of Visnadin, Ethyl Ximeninate, Coleus Barbatus and Millet in Emulgel on Sexual Function in Postmenopausal Women With Vulvovaginal Atrophy, a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chulalongkorn University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chulalongkorn University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial, a double blind randomized controlled trial, is conducted to determine&#xD;
      the effects of daily topical visnadin, ethyl ximeninate, coleus barbatus and millet in&#xD;
      emulgel on sexual function in postmenopausal women with vulvovaginal atrophy within 8-week of&#xD;
      treatment. We compare the active ingredient in emulgel to the emulgel only. We also evaluate&#xD;
      the improvement of the vulvovaginal atrophy symptoms in postmenopausal women, the safety and&#xD;
      the tolerability of visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel. This&#xD;
      study is conducted in the Menopause Clinic and the Gynecology Clinic, King Chulalongkorn&#xD;
      Memorial Hospital, Bangkok, Thailand.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel is a cosmetic&#xD;
      product. Visnadin is an active ingredient which has the vasodilator effect and improve blood&#xD;
      flow to female vulvovaginal area. This will improve lubrication from increase Bartholin's&#xD;
      gland secretion. As the clitoral blood flow increase, the sexual response could be improved.&#xD;
      The ethyl ximeninate, coleus barbatus and millet are plant extract which have moisturizer,&#xD;
      anti-inflammation and antioxidant effects. Our hypothesis is a daily topical visnadin, ethyl&#xD;
      ximeninate, coleus barbatus and millet in emulgel could improved sexual function and&#xD;
      vulvovaginal atrophic symptoms in postmenopausal women with vulvovaginal atrophy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 27, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Pharmacist will provide the same color and texture of product and identical package for both active emulgel and emulgel only products. She is the only person who knows the code of product and prepare the product in the opaque envelop for all participants.&#xD;
The statistician will generate the code of product to all participants with block-of-four randomization method.&#xD;
The nurse will distribute and help the participants fill all questionnaires.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Sexual function</measure>
    <time_frame>8-week</time_frame>
    <description>Female Sexual Function Index (FSFI) The full scale (overall) score of the FSFI can be derived from the six domain scores; desire, arousal, lubrication, orgasm, satisfaction and pain. The minimum value is 2.0 and maximum value is 36.0, and the higher scores mean a better outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vulvovaginal atrophic symptoms score</measure>
    <time_frame>8-week</time_frame>
    <description>4-likert scale; 0 = no symptom, 1= mild symptom, 2 = moderate symptom, 3 = severe symptom The minimum is 0 and maximum value is 4, and the higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event and tolerability</measure>
    <time_frame>8-week</time_frame>
    <description>Possible adverse event of therapeutic use</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Female Sexual Function</condition>
  <condition>Vulvovaginal Atrophy</condition>
  <condition>Postmenopausal Atrophic Vaginitis</condition>
  <arm_group>
    <arm_group_label>Active Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Apply small amount of topical visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Apply small amount of topical emulgel-only on mucosal surface of vulva included clitoris every day before bedtime for 8-week period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Visnadin, ethyl ximeninate, coleus barbatus and millet in emulgel</intervention_name>
    <description>Topical product, apply small amount on mucosal surface of vulva included clitoris once daily</description>
    <arm_group_label>Active Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Emulgel-only</intervention_name>
    <description>Topical placebo product, apply small amount on mucosal surface of vulva included clitoris once daily</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women age 45-65 years old&#xD;
&#xD;
          -  BMI 19-29 kg/m2&#xD;
&#xD;
          -  Menopause or removal of both ovaries more than 1 year&#xD;
&#xD;
          -  Has moderate to severe vulvovaginal atrophic at least 1 symptom&#xD;
&#xD;
          -  Has sign of vulvovaginal atrophy&#xD;
&#xD;
          -  Vaginal pH â‰¥ 5&#xD;
&#xD;
          -  Has sexual intercourse at least 1 time/month&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hormonal use within 3 months&#xD;
&#xD;
          -  Use vaginal estrogen/ moisturizer within 3 months&#xD;
&#xD;
          -  Use aromatase inhibitor/tamoxifen within 3 months&#xD;
&#xD;
          -  Has vaginal bleeding within 6 months&#xD;
&#xD;
          -  Acute or chronic urinary tract infection&#xD;
&#xD;
          -  History of radiation therapy at vulvovaginal and pelvic area&#xD;
&#xD;
          -  History of Diabetes mellitus or Cardiovascular disease&#xD;
&#xD;
          -  History of neurosis or psychosis&#xD;
&#xD;
          -  History of vulvovaginal cancer&#xD;
&#xD;
          -  History of smoking more than 20 cigarettes/day&#xD;
&#xD;
          -  History of alcoholic drink/ drug abuse&#xD;
&#xD;
          -  History of visnadin, ethyl ximeninate, coleus barbatus and millet allergy&#xD;
&#xD;
          -  Has disease of vulva&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Postmenopausal women</gender_description>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sukanya Chaikittisilpa, MD,MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chulalongkorn University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sukanya Chaikittisilpa, MD,MSc</last_name>
    <phone>+66915615415</phone>
    <email>sukanya.c@chula.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nalina Orprayoon, MD</last_name>
    <phone>+66909908440</phone>
    <email>nalina.o@chula.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine, Chulalongkorn University</name>
      <address>
        <city>Pathum Wan</city>
        <state>Bangkok</state>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sukanya Chaikittisilpa</last_name>
      <phone>+66915615415</phone>
      <email>sukanya.c@chula.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Nalina Orprayoon</last_name>
      <phone>+66909908440</phone>
      <email>nalina.o@chula.ac.th</email>
    </contact_backup>
    <investigator>
      <last_name>Sukanya Chaikittisilpa, MD,MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nalina Orprayoon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vulvovaginal atrophy</keyword>
  <keyword>Genitourinary Syndrome of Menopause</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>Female sexual function</keyword>
  <keyword>Visnadin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Atrophic Vaginitis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

